Dexcom– tag –
-
CNET Reviews 2026’s Latest Continuous Glucose Monitors (CGM), Highlighting FDA-Approved Dexcom Stelo’s Integration with Oura Ring
CNET USA Overview CNET's 2026 review of Continuous Glucose Monitors (CGM) features Abbott Freestyle Libre 2 and 3 Plus, Dexcom G7, and the notable Stelo by Dexcom, the first FDA-approved over-the-counter CGM in the US (2024). Stelo's sea... -
Senseonics Eversense 365 Receives FDA Approval as World’s First Year-Long Wearable CGM, Expanded Medicare Coverage to Reshape Market
Constancy Researchers America Overview Senseonics' Eversense 365 has secured FDA approval, becoming the world's first commercially available year-long implantable continuous glucose monitor (CGM). This innovation fundamentally improves p... -
Dexcom Stelo Wins FDA Approval as First Prescription-Free OTC Continuous Glucose Monitor for Non-Insulin Users
Dexcom (via Facebook) USA Overview Dexcom's Stelo glucose biosensor system has received FDA approval as the first over-the-counter (OTC) continuous glucose monitor (CGM) for adults aged 18 and older who do not use insulin. This landmark ... -
Dexcom Achieves 13% Q2 Revenue Growth as FDA Approves OTC Glucose Biosensor Stelo for Pediatric Use
Medical Design and Outsourcing USA Overview Dexcom reported a robust 13% year-over-year revenue growth in Q2 2026, demonstrating the efficacy of its CGM technology in non-insulin-using Type 2 diabetes patients. Concurrently, the U.S. FDA... -
Dexcom Expands Beyond Diabetes Sensors to Comprehensive Health Platform with G8 Launch, Stelo Introduction, and FDA TEMPO Program Inclusion
Libre Life USA Overview Dexcom is transforming from a diabetes sensor manufacturer into a broader connected health platform, marked by the announcement of its next-gen G8 CGM, a 15-day wear extension for G7 internationally, and the launc... -
FDA Clears Dexcom’s Stelo Glucose Biosensor System as First OTC Continuous Glucose Monitor for Non-Insulin-Using Children Ages 2+
Weence.com USA Overview On June 12, 2026, the FDA approved Dexcom's Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM) for children aged 2 and older who do not use insulin. This system, wh... -
DexCom Reports Strong Q2 2026 Results with 13% Revenue Growth, 50% Operating Income Surge
Stock Titan USA Overview DexCom announced robust Q2 2026 financial results, with revenue up 13% year-over-year, driven by increased disposable sensor volumes and an expanding customer base. The company also reported a significant 50% ris... -
Dexcom G7 Achieves Industry-Leading Accuracy with MARD 8.2-8.5% in Adults, Clinical Data Confirms
diabetesknow.com USA Overview Newly compiled clinical data for 2026 ranks the Dexcom G7 as the most accurate continuous glucose monitor (CGM), reporting a mean absolute relative difference (MARD) of approximately 8.2–8.5% in adults. This... -
FDA Clears Dexcom’s Stelo OTC Continuous Glucose Monitor for Non-Insulin Users Aged Two and Up
Prime Therapeutics - Portal USA Overview The FDA has granted over-the-counter (OTC) marketing authorization for Dexcom's Stelo Glucose Biosensor System, expanding its use to non-insulin users aged two and older. This marks the first OTC ... -
FDA Selects Dexcom as Inaugural Participant in Digital Health Pilot to Accelerate AI-Integrated Glucose Management
Healthcare Dive USA Overview The U.S. FDA has named Dexcom as the first participant in its new digital health pilot program, designed to streamline regulatory pathways for innovative devices. This initiative will exempt certain Dexcom di...
